EverPoint Asset Management’s PTC Therapeutics PTCT Stock Holding History

EverPoint Asset Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$109K	Sell	10,000 -65,000	-87%	-$682K	﹤0.01%	398
2016 Q3	$1.05M	Buy	+75,000	New	+$610K	0.02%	380
2015 Q4	–	Sell	-325,000	Closed	-$8.68M	–	512
2015 Q3	$8.68M	Buy	325,000 +265,000	+442%	+$11.3M	0.23%	134
2015 Q2	$2.89M	Buy	+60,000	New	+$3.5M	0.05%	353
2015 Q1	–	Sell	-229,400	Closed	-$11.9M	–	571
2014 Q4	$11.9M	Buy	229,400 +59,400	+35%	+$2.61M	0.27%	125
2014 Q3	$7.48M	Buy	+170,000	New	+$5.32M	0.17%	197

Other funds holding PTCT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

EverPoint Asset Management's PTCT Position: Q4 2016 in Review

EverPoint Asset Management reduced its PTC Therapeutics (PTCT) stake by 87% in Q4 2016, selling an estimated $682K and leaving 10,000 shares worth $109K. The position accounts for ﹤0.01% of the portfolio, ranked #398.

EverPoint Asset Management first reported a position in PTCT in Q3 2014 and has held it in 6 quarters since. The position peaked at $11.9M in Q4 2014. 123 funds tracked by Wall St. Rank hold PTCT as of Q4 2016.

EverPoint Asset Management held 10,000 shares of PTC Therapeutics worth $109K as of Q4 2016.
EverPoint Asset Management sold 65,000 PTC Therapeutics shares in Q4 2016, an estimated $682K.
PTC Therapeutics made up ﹤0.01% of EverPoint Asset Management's portfolio in Q4 2016, its #398 holding.
EverPoint Asset Management first reported a position in PTC Therapeutics in Q3 2014 and has held it in 6 quarters since.
EverPoint Asset Management's PTC Therapeutics position peaked at $11.9M in Q4 2014.
123 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.